Menlo: Serlopitant Fails To Show Efficacy In Treating Refractory Chronic Cough

(RTTNews) - Menlo Therapeutics Inc. (MNLO) reported top-line results from MTI-110 (TUSSIX), its Phase 2 clinical trial of serlopitant for the treatment of refractory chronic cough. The company said in the 185 patient study, treatment with serlopitant failed to demonstrate benefit versus placebo on the primary and key secondary endpoints.

Steve Basta, CEO of Menlo Therapeutics, said: "Based upon the results of this trial, we do not anticipate further development of serlopitant for the treatment of refractory chronic cough. We are continuing the clinical development of serlopitant for pruritus associated with various conditions given the two successful Phase 2 clinical trials in which serlopitant demonstrated a reduction in chronic pruritus and pruritus associated with prurigo nodularis."